Lipoproteína(a)
Grupo Argentino Estudio Lipoproteína (a)
.png)
Últimas Novedades
J Int Med Res. 2026 Apr;54(4):3000605261436667. doi: 10.1177/03000605261436667. Epub 2026 Apr 30.
Autores:
Zhe Liu 1 , Hui Li 2 , Wen Chang 3 , Baoyu Geng 1 , Lei Wu 1 , Zhen Chen 1
Front Endocrinol (Lausanne). 2026 Apr 13:17:1780579. doi: 10.3389/fendo.2026.1780579. eCollection 2026.
Autores:
Feifei Wang # 1 2 , Jiangnan Wu # 3 , Hongling Li # 4 , Shijie Gao 2 , Zhuohan Zheng 2 , Zhiheng Wang 1 2 , Jing Gao 1
Conclusión: Low Lp(a) levels within the first 20 weeks of gestation were associated with the subsequent development of GDM, independent of maternal age and pre-pregnancy BMI.
Pharmacol Res. 2026 May:227:108178. doi: 10.1016/j.phrs.2026.108178. Epub 2026 Apr 3.
Autores:
An-Xin Wu 1 , Xing-Jin Wang 2 , Chen Zhao 3 , Jia-Qiang Hu 4 , Jin-Wei Li 5 , Ying Xu 6 , Yi Li 7 , Song Liu 8
Pol Arch Intern Med. 2026 Apr 29;136(4):17253. doi: 10.20452/pamw.17253. Epub 2026 Mar 17.
Autores:
Grzegorz Procyk, Paweł Tyrna, Izabela Młynarczuk-Biały, Jan Budzianowski, Anna Olasińska-Wiśniewska, Janusz Kochman, Aleksandra Gąsecka
Conclusión: The patients with elevated Lp(a) level had a comparable risk of 12‑month MACCE after TAVI to those with low Lp(a) level but might have worse long‑term survival. Long‑term findings should be considered exploratory and require further confirmation.
Am Heart J. 2026 Jul:297:107423. doi: 10.1016/j.ahj.2026.107423. Epub 2026 Mar 7.
Autores:
Emiliano Bianchini 1 , Sara Essa Alsubai 2 , Foziyah Alqahtani 2 , Sara Sgreva 3 , Paolo Alberto Del Sole 1 , Aduba Chukwunwike 4 , Despina Abrasheva 5 , Vasanth Cherin 4 , Hesham Elzomor 4 , Ruth Sharif 6 , Michael G Madden 7 , Faisal Sharif 8
Conclusión: Distinct biomarker signatures associate with distinct CAD prevalence and severity that conventional lipid markers fail to distinguish. Lp(a) appears relevant for early plaque detection in coronary artery calcium = 0 patients. A comprehensive biomarker evaluation may help identifying high-risk subgroups overlooked by a conventional assessment.
Am J Cardiol. 2026 May 15:267:97-103. doi: 10.1016/j.amjcard.2026.02.038. Epub 2026 Feb 26.
Autores:
Eleni Adamopoulou 1 , Kyriakos Dimitriadis 2 , Athanasios Sakalidis 3 , Konstantinos Kyriakoulis 3 , Alexandros Koulouriotis 3 , Nikolaos Pyrpyris 3 , Konstantinos Aznaouridis 3 , Philippos Orfanos 4 , Pagona Lagiou 4 , Konstantinos Tsioufis 3
Adv Med Sci. 2026 Mar;71(1):68-74. doi: 10.1016/j.advms.2026.02.006. Epub 2026 Feb 26.
Autores:
Joanna Popiolek-Kalisz 1 , Pierre Sabouret 2
Conclusión: In high cardiovascular risk patients, Lp(a) appears unrelated to body composition, supporting its role as a non-modifiable, genetically driven risk factor. Conversely, despite pharmacotherapy, HDL-C and triglycerides demonstrated significant associations with body fat distribution. These findings suggest clinical role of body composition assessment in cardiovascular risk management, particularly in addressing residual risk beyond LDL-C.
Curr Opin Lipidol. 2026 Jun 1;37(3):107-112. doi: 10.1097/MOL.0000000000001029. Epub 2026 Feb 13.
Autores:
Martine Paquette 1 , Simon-Pierre Guay 2 , Alexis Baass 1 3
Curr Opin Lipidol. 2026 Jun 1;37(3):93-99. doi: 10.1097/MOL.0000000000001032. Epub 2026 Feb 10.
Autores:
Ali K Jaafar 1 , Steeve Bourane 2 , Gilles C Lambert 2 , Kevin Chemello 3
Eur Heart J Cardiovasc Imaging. 2026 Apr 30;27(5):1012-1021. doi: 10.1093/ehjci/jeag024.
Autores:
Rebecca Fisher 1 , Chen Gurevitz 2 3 , Edward A Fisher 1 , Jisuk Park 4 , Melissa Aquino 4 , Sascha N Goonewardena 5 , Robert S Rosenson 2
Conclusión: In asymptomatic primary prevention patients, Lp(a) was independently associated with high-risk coronary plaque features, specifically LDNCP, beyond traditional risk enhancers. These findings highlight the unique role of Lp(a) in identifying coronary plaque vulnerability and suggest complementary roles for Lp(a) and CAC in refining cardiovascular risk stratification.